Articles On Proteomics International Laboratories (ASX:PIQ)

Proteomics International Laboratories (ASX:PIQ) has announced it has signed a distribution licensing agreement for the immunoassay version of the PromarkerD predictive test for diabetic kidney disease.

ASX-listed medical technology company, Proteomics International Laboratories, has entered into an agreement with Medical Horizons that will see the Italy-based group distribute the easy-to-use immunoassay version of Proteomics’ PromarkerD p...

Australian company Proteomics International (ASX:PIQ) says it has secured patents for PromarkerD, a low cost, high throughput predictive test for diabetic kidney disease, in Brazil and Canada.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Towards th...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Medical technology company Proteomics International Laboratories (ASX: PIQ) announced that a global multi-centre study of 3,000 people has confirmed the effectiveness of PromarkerD as a predictive test for diabetic kidney disease. The colla...

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, has secured CE Mark registration for its PromarkerD Immunoassay kit as an IVD medical device (in vitro diagnostic). PromarkerD (IA) forms part of the...

Proteomics International Laboratories (PIQ) has secured CE Mark registration for the PromarkerD Hub The PromarkerD Hub is a software tool used to calculate the risk of kidney disease in patients with type 2 diabetes Proteomics will now p...

Orthocell (ASX:OCC) has found a new use for its CelGro tech – anterior cruciate ligament (ACL) injuries. The ACL is a major stabilising ligament in the knee. Once it is ruptured, it cannot be healed it must be replaced and recovery takes se...

Proteomics International Laboratories (ASX: PIQ) has embarked on a European commercialisation campaign following the launch of PromarkerD – its predictive diagnostic test for diabetic kidney disease – in Spain. The Spanish launch marks the...

Biotech company Mesoblast (ASX:MSB) has entered into a strategic partnership to develop and commercialise a stem cell treatment for chronic lower back pain. As part of the deal, Mesoblast said it could receive up to $150m ($218.6m) in up-fr...

Concurrently, TGA regulatory approval granted for PromarkerD software as an in vitro diagnostic for export use.

Australian healthcare industry challenges include an ageing population, increased rate of chronic diseases, emergence and integration of new technologies, etc. Some important Australian companies, which are working on integrating ‘SaaS’ mod...

Australia’s cannabis industry continues to edge forward under the watchful eye of regulators. For now, it’s the Office of Drug Control’s world — and domestic cannabis companies just live in it. Scroll down for more ASX cannabis news >&gt...

Perth-based Proteomics International Laboratories (ASX:PIQ) says it has been invited to feature on the American Diabetes Association TV News Network during the ADA 79th Scientific Sessions conference in San Francisco.